Expert analysis
Analysts delivered insights on the trends influencing drug pipelines, mergers and acquisitions, drug pricing, and more
Why this matters
The JPM Healthcare Conference offers an early view of investor sentiment in the industry, but identifying the most relevant trends amid the noise can be challenging.
This post-conference report from GlobalData Healthcare distils the conference's key insights through a GlobalData lens, highlighting major biopharmaceutical trends and notable developments across therapy areas to provide a clear perspective on the outlook for 2026.
GlobalData Healthcare Expert View
Deep proprietary insight
Exclusive analysis across pipelines, clinical trials, and deal activity, enriched by GlobalData datasets
Analyst interpretation
Clear explanation of company strategies and their implications for the healthcare industry in 2026, designed for executive leadership, strategy, BD&L, and R&D teams
Watch The Post-JPM 2026 Webinar
Following the JP Morgan Healthcare Conference, GlobalData Healthcare analysts hosted a dedicated briefing to unpack the most important strategic signals from JPM 2026.
This on-demand webinar builds on the findings from the post-conference report, expands on key themes across pipelines, partnerships, and M&A, explaining the meaning of these trends for healthcare strategies in the year ahead.
Why GlobalData?
One unified intelligence platform
Proprietary data, expert analysis, and purpose-built AI connected in a single decision engine, giving you clarity on what’s coming and why it matters.
Depth and expertise you can trust
3,000 in-house subject matter experts and unrivalled datasets providing a complete, connected view of the healthcare landscape.
Built to accelerate action
AI-powered intelligence that reduces time from insight to decision, helping 5,000+ organizations move faster, de-risk choices, and lead with confidence.